Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Kezar Life Sciences Inc
Healthcare
P/NCAV
0.35x
Ticker
KZR
Exchange
NASDAQ
Country
United States
Close
0.83 $
Mkt Cap
59.9M $
EV
34.5M $
NCAV Burn Rate
32.3%
Current Ratio
11.66
Debt/Equity
0.05
EV/REV
4.93x
EV/EBIT
-0.3x
EV/FCF
-0.4x
Dilution
21.7% p.A
Total Net Income
-342.2M $
Cheapness
99.0%
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company-s lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average